Should β-Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease?

Seminars in Nephrology

Volumn 27, Issue 5, 2007, Pages 555-564

  Hart, Peter D ^a   Bakris, George L ^b  

^a Jr Hospital of Cook County   (United States)

^b Section of Endocrinology Diabetes and Metabolism   (United States)

Author keywords

blockers; hypertension; kidney disease

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; LABETALOL; METOPROLOL; METOPROLOL TARTRATE; PLACEBO; PROPRANOLOL; RAMIPRIL;

ADRENERGIC SYSTEM; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; DRUG USE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY ALLOGRAFT REJECTION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; MONOTHERAPY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; TREATMENT OUTCOME;

EID: 34548531553     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.07.003     Document Type: Article

References (98)

1. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: finding from the third national Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161 (2001) 1207-1216
2. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 Suppl 1 (2004) S1-S290
3. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to know? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32 (1998) 853-906
4. Antman E.M., Anbe D.T., Armstrong P.W., et al. A guideline for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 110 (2004) 588-636
5. Bakris G.L. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens 16 (2003) 7S-12S
6. Salomonsson M., Brannstrom K., and Arendshorst W.J. Alpha(1)-adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies. Am J Physiol 278 (2000) F138-F147
7. Epstein M., Oster J.R., and Hollenberg N.K. b-blockers and the kidney: implications for renal function and renin release. Physiologist 28 (1985) 53-63
8. DiBona G.F. Neural control of the kidney: past, present, and future. Hypertension 41 (2003) 621-624
9. Campese V.M., and Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 4 (2002) 256-260
10. Ye S., Ozgur B., and Campese V.M. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51 (1997) 722-727
11. Campese V.M., and Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25 (1995) 878-882
12. Ye S., Zhong H., Yanamadala V., et al. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15 (2002) 717-724
13. Salplachta J., Bartosikova L., and Necas J. Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys 21 (2002) 189-195
14. Amann K., Nichols C., Tornig J., et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11 (1996) 1003-1011
15. Klein I.H., Ligtenberg G., Oey P.L., et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12 (2001) 2427-2433
16. Ligtenberg G., Blankestijn P.J., Oey P.L., et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340 (1999) 1321-1328
17. Converse Jr. R.L., Jacobsen T.N., Toto R.D., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327 (1992) 1912-1918
18. Klein I.H.H.T., Lightenberg G., Neumann J., et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14 (2003) 3239-3244
19. Neumann J., Lightenberg G., Klein I.H., et al. Sympathetic hyperactivity in hypertensive chronic kidney disease is reduced during standard treatment. Hypertension 49 (2007) 506-510
20. Hausberg M., Kosch M., Harmelink P., et al. Sympathetic nerve activity in end-stage renal disease. Circulation 106 (2002) 1974-1979
21. Zoccali C., Mallamaci F., Parlongo S., et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105 (2002) 1354-1359
22. Orth S.R., Amann K., Strojek K., et al. Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant 16 (2001) S67-S69
23. Paoletti E., Specchia C., Di Maio G., et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 19 (2004) 1829-1834
24. Eknoyan G. On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes. Am J Kidney Dis 32 (1998) S1-S4
25. Zuanetti G., Maggioni A.P., Keane W., et al. Nephrologists neglect administration of beta blockers to dialysed diabetic patients. Nephrol Dial Transplant 12 (1997) 2497-2500
26. Abbott K.C., Trespalacios F.C., Agodoa L.Y., et al. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 164 (2004) 2465-2471
27. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
28. Foley R.N., Herzog C.A., and Collins A.J. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int 62 (2002) 1784-1790
29. Horl M.P., and Horl W.H. Drug therapy for hypertension in hemodialysis patients. Semin Dial 17 (2004) 288-294
30. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41 (2003) 1438-1444
31. Trespalacios F.C., Taylor A.J., Agodoa L.Y., et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 62 (2002) 1799-1805
32. Wright R.S., Reeder G.S., Herzog C.A., et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137 (2002) 563-570
33. Bakris G.L., Hart P., and Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 70 (2006) 1905-1913
34. Meier J. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am Heart J 104 (1982) 364-373
35. Borchard U. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem 8 Suppl 2 (1990) 28-34
36. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 41 (1998) 39-52
37. Jacob S., Rett K., and Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?. Am J Hypertens 11 (1998) 1258-1265
38. Giugliano D., Acampora R., Marfella R., et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
39. Jacob S., Rett K., Wicklmayr M., et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 14 (1996) 489-494
40. Williams M.E., Gervino E.V., Rosa R.M., et al. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med 312 (1985) 823-827
41. Arrizabalaga P., Montoliu J., Martinez V.A., et al. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc 20 (1983) 572-576
42. Mehrotra S., Ling K.L., Bekele Y., et al. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with type 2 diabetes mellitus. Diabet Med 18 (2001) 109-115
43. Onozato M.L., Tojo A., Goto A., et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61 (2002) 186-194
44. Ueno Y., Kizaki M., Nakagiri R., et al. Dietary glutathione protects rats from diabetic nephropathy and neuropathy. J Nutr 132 (2002) 897-900
45. Dupont A.G. Carvedilol and the kidney. Clin Invest 70 Suppl 1 (1992) S127-S131
46. Epstein M., and Oster J.R. Beta blockers and renal function: a reappraisal. J Clin Hypertens 1 (1985) 85-99
47. Abbott K.C., and Bakris G. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol 33 (1993) 392-399
48. Zech P., Pozet N., Labeeuw M., et al. Acute renal effects of beta-blockers. Am J Nephrol 6 Suppl 2 (1986) 15-19
49. Sugino G., Barg A.P., and O'Connor D.T. Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension. Am J Kidney Dis 3 (1984) 357-361
50. Dreslinski G.R., Messerli F.H., Dunn F.G., et al. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension. Circulation 65 (1982) 1365-1368
51. Yasumoto R., Asakawa M., Kakinoki K., et al. [Effect of metoprolol in patients with renal hypertension.]. Hinyokika Kiyo 34 (1988) 1669-1673
52. van Zwieten P.A. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs 45 (1993) 509-517
53. Malini P.L., Strocchi E., Negroni S., et al. Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol 13 (1982) 123S-126S
54. Wallin J.D. Adrenoreceptors and renal function. J Clin Hypertens 1 (1985) 171-178
55. Keusch G., Weidmann P., Ziegler W.H., et al. Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. Klin Wochenschr 58 (1980) 25-29
56. Cruz F., O'Neill Jr. W.M., Clifton G., et al. Effects of labetalol and methyldopa on renal function. Clin Pharmacol Ther 30 (1981) 57-63
57. Rasmussen S., and Nielsen P.E. Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension. Br J Clin Pharmacol 12 (1981) 349-353
58. Dupont A.G., Van der N.P., Taeymans Y., et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 10 Suppl 11 (1987) S130-S136
59. Calo L.A., Semplicini A., and Davis P.A. Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients. Am J Med 118 (2005) 201-202
60. Tomita K., and Makumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 19 Suppl 1 (1992) S97-S101
61. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 36 (2000) 646-661
62. UKPD Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317 (1998) 713-720
63. Parving H.H., Andersen A.R., Smidt U.M., et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294 (1987) 1443-1447
64. Cook M.E., Wallin J.D., Clifton G.G., et al. Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity. Clin Pharmacol Ther 43 (1988) 393-399
65. Kohno M., Takeda T., Ishii M., et al. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan. Drugs 36 Suppl 6 (1988) 129-135
66. Takeda T., Kohno M., Ishii M., et al. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. Eur J Clin Pharmacol 38 Suppl 2 (1990) S158-S163
67. Bjorck S., Mulec H., Johnsen S.A., et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 304 (1992) 339-343
68. Hannedouche T., Landais P., Goldfarb B., et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309 (1994) 833-837
69. Lacourciere Y., Nadeau A., Poirier L., et al. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21 (1993) 786-794
70. Apperloo A.J., de Zeeuw D., Sluiter H.E., et al. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 303 (1991) 821-824
71. Himmelmann A., Hansson L., Hansson B.G., et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 4 (1995) 85-90
72. Wright J.T., Bakris G., and Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288 (2002) 2421-2431
73. Seiler K.U., Schuster K.J., Meyer G.J., et al. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet 5 (1980) 192-198
74. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55 (1999) 1528-1535
75. Branten A.J., Hilbrands L.B., van Hamersvelt H.W., et al. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrol Dial Transplant 13 (1998) 423-426
76. Kirch W., Kohler H., Mutschler E., et al. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 19 (1981) 65-71
77. Jordo L., Attman P.O., Aurell M., et al. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet 5 (1980) 169-180
78. Suwelack B., Kobelt V., Erfmann M., et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 16 (2003) 313-320
79. Hara Y., Hamada M., Shigematsu Y., et al. Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients. Clin Sci (Lond) 101 (2001) 219-225
80. McCauley J., Murray J., Jordan M., et al. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol 22 (2002) 347-351
81. Hamad A., Salameh M., Zihlif M., et al. Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol 21 (2001) 241-244
82. Gehr T.W., Tenero D.M., Boyle D.A., et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 55 (1999) 269-277
83. Miki S., Masumura H., Kaifu Y., et al. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. J Cardiovasc Pharmacol 18 Suppl 4 (1991) S62-S68
84. Masumura H., Miki S., Kaifu Y., et al. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. J Cardiovasc Pharmacol 19 Suppl 1 (1992) S102-S107
85. Deetjen A., Heidland A., Pangerl A., et al. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients. Clin Nephrol 43 (1995) 47-52
86. Nowicki M., Szewczyk-Seifert G., Klimek D., et al. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 57 (2002) 352-358
87. Calo L., Giacon B., Davis P.A., et al. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clin Nephrol 58 (2002) 103-110
88. Kaijser M., Johnsson C., Zezina L., et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant 11 (1997) 577-581
89. Leeman M., Vereerstraeten P., Uytdenhoef M., et al. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients. J Cardiovasc Pharmacol 22 (1993) 706-710
90. Rahman M., and Smith M.C. Chronic renal insufficiency: a diagnostic and therapeutic approach. Arch Intern Med 158 (1998) 1743-1752
91. Harnett J.D., Foley R.N., Kent G.M., et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47 (1995) 884-890
92. Marchi F., and Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 12 (1995) 212-221
93. Agrawal B., Wolf K., Berger A., et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 10 (1996) 551-555
94. Fassbinder W., Quarder O., and Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract 53 (1999) 519-522
95. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
96. Bakris G.L., Fonseca V., Katholi R.E., et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46 (2005) 1309-1315
97. Giner V., Tormos C., Chaves F.J., et al. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 255 (2004) 588-594
98. Raats C.J., Bakker M.A., van den B.J., et al. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 272 (1997) 26734-26741